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April 20091084 Abstractsof lowering LDL-C with statins alone vs statins plus ezetimibe on common
CIMT in patients with type 2 diabetes and no known prior cardiovascular
events. The SANDS Trial was a randomized, open labeled, blinded to
outcomes, 3-year trial examining the effects of aggressive goals for LDL-C
(70 mg/dL) non-high-density lipoprotein cholesterol (100 mg/dL)
and blood pressure (115/75 mm Hg) reduction vs standard goals of
100 mg/dL, 130mg/dL, and 130/80 mm Hg, respectively, in 499
Native American patients with type 2 diabetes. The primary outcome was
change in CIMT after 36 months of treatment.
Ezetimibe is an antihyperlipidemic medication used to lower cholesterol
levels. It acts by decreasing cholesterol absorption in the intestine and can be
used alone or with other cholesterol-lowering medications. It is generally
indicated for use when cholesterol levels cannot be controlled with statins alone.
The authors compared CIMT levels for 36 months in diabetic individ-
uals aged 40 years receiving statins plus ezetimibe vs statins alone. The
CIMT changes in both aggressive subgroups were compared with changes in
the standard subgroups. LDL-C was reduced by 31 mg/dL (range, 23-37
mg/dL) and 32 mg/dL (range, 27-38 mg/dL) in the aggressive group by
statins plus ezetimibe and statins alone, respectively. This was compared with
changes of 1 mg/dL (range3 to 6 mg/dL) in the standard group vs both
aggressive subgroups (P  .0001). Within the aggressive group, mean
CIMT at 36 months regressed in the ezetimibe and nonezetimibe subgroups
but progressed in the standard treatment arm (0.025,0.012, and 0.039
mm, respectively; P  .0001).
Comment: CIMT is considered a marker of future cardiovascular risk
and thus can serve as a short-term surrogate for potential long-term cardio-
vascular events. The current trial has, therefore, two potential significant
implications. The first is that ezetimibe does not provide any advantage over
a statin alone in reducing long-term cardiovascular risk. The results would
therefore seem to confirm the Enhanced Trial (N Engl J Med 2008;358:
1431-43) of 720 patients with familial hypercholesterolemia where there
was no statistically significant difference in the primary end point of mean
increase in CIMT over 24 months in the patients treated with statins alone
vs statin plus ezetimibe. The second point is that it does appear possible to
actually reduce surrogate markers of future atherosclerosis by aggressively
lowering cholesterol beyond standard target levels. In its early stages,
atherosclerosis may be a reversible disease.
Evaluation of Wells Score and Repeated D-Dimer in Diagnosing Ve-
nous Thromboembolism
Ljungqvist M, Soderberg M, Moritz P, et al. Eur J Intern Med 2008;19:
285-8.
Conclusion:A normal pretest probability score using Wells criteria and
a normal D-dimer level safely excludes venous thromboembolism (VTE) in
emergency department patients.
Summary: Evaluation of possible VTE is common in the emergency
department. Overall, 25% of the patients evaluated for VTE in the emer-
gency department will actually have the disease. The authors sought to
determine if a low pretest probability score (PTP) using Wells criteria,
together with a normal D-dimer level, could safely exclude VTE in outpa-
tients and if a follow-up D-dimer study would add additional information to
the initial evaluation. Excluded were 177 patients (54% women) with
D-dimer levels 0.5 mg/dL and a PTP of 1.5. Of these, 25% had VTE.
The study included 151 patients (68% women) with suspected VTE and who
had a PTP1.5 and a D-dimer test (TinaQuant) result0.5 mg/L but who
underwent no further initial diagnostic investigations. A follow-up D-dimer
test was conducted 3 to 7 days after the initial hospital visit. If this test result
was abnormal, further diagnostic investigations were made.
A follow-up D-Dimer test was conducted in 101 of 151 patients (67%),
and 13 had elevated D-dimer levels. None of these patients were diagnosed
with VTE or had persistent symptoms. After 3 months, all 151 of these
patients were contacted and none had clinical signs of VTE.
Comment: These data support the use of a clinical algorithm that
includes both the Wells criteria PTP score and D-dimer levels to reduce the
number of ultrasound investigations in patients with a low risk of VTE.
There were no symptomatic VTEs3 months in 151 patients with low PTP
and a normal D-dimer level. A follow-up D-dimer test did not add clinically
important information. There are many assays for D-dimer. The data here
apply only to that assay used in this study.
Glucose Control and Vascular Complications in Veterans with Type 2
Diabetes
Duckworth W, Abraira C, Moritz T. N Engl J Med 2009;360;129-39.
Conclusion: In patients with previously poorly controlled type 2 diabetes,
use of intensive glucose control vs standard glucose control did not affect rates
of major cardiovascular events, death, or microvascular complications.
Summary: The authors sought to determine the effects of intensive
glucose control on cardiovascular events in patients with longstanding type
2 diabetes. There were 1791 veterans (mean age, 60.4 years), all of whom
had suboptimal response to therapy for type 2 diabetes, randomized toeither standard or intensive glucose control. All other cardiovascular risk
factors were treated the same in both groups. The diagnosis of diabetes was
present for a mean of 11.5 years, and 40% had sustained a previous cardio-
vascular event. An absolute reduction of 1.5 percentage points in the
hemoglobin A1C level was the goal for the intensive therapy group compared
with the standard therapy group. Primary outcome was time from random-
ization to the occurrence of the first major cardiovascular event, defined as
composite of myocardial infarction, stroke, death from cardiovascular
causes, congestive heart failure, surgery, or intervention for vascular or
coronary disease, and amputation for ischemic gangrene.
Median follow-up was 5.6 years. Median hemoglobin A1C was 8.4% in
the standard-therapy group and 6.9% in the intensive-therapy group. The
primary outcome occurred in 264 patients in the standard-therapy group
and 235 patients in the intensive-therapy group (0.88; 95% confidence
interval [CI], 0.74-1.05; P  .14). Between the two groups, there were no
differences in the occurrence of any components of the primary outcome or
in the rate of death from any cause (hazard ratio, 1.07; 95% CI, 0.81-1.42;
P  .62). There was also no difference in microvascular complications
between the two groups. Adverse events, predominantly hypoglycemia,
occurred in 17.6% of the standard-therapy and 24.1% in the intensive-
therapy groups respectively.
Comment: Many interventions can affect prognosis in patients with type
2 diabetes, including lifestyle changes, control of blood pressure and lipids, and
use of antiplatelet agents. Blood pressure control appears to have better benefit
than glucose control (BMJ 1998;317:703-13). Previously, there had been
mixed results about whether glucose control can independently reduce cardio-
vascular complications in patients with advanced type 2 diabetes. The UK
Prospective Diabetes Study (BMJ 1998;317:703-13), the Action in Diabetes
and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation
(ADVANCE) Trial (N Engl J Med 2008;358:2560-72), and the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) Trial (N Engl J Med
2008;358:2545-59) all studied the effects of intensive glucose control in pa-
tients with diabetes. None of these studies, and now the current study, provided
significant evidence for favorable effects of intensive glucose control in control-
ling cardiovascular events in patients with diabetes. Some, in fact, even sug-
gested harm from this approach. At this point we can say that intensive glucose
control early in the course of patients with diabetes may be of benefit; however,
in patients with well-established diabetes, it appears that management of other
cardiovascular risk factors, such as hypertension and increased lipids, is a more
effective approach to preventing cardiovascular morbidity and mortality than
tight glucose control.
The Obesity Paradox in Patients With Peripheral Arterial Disease
Galal W, van Gestle YRBM, Hoeks SE, et al. Chest 2008;134:925-30.
Conclusion: The presence of chronic obstructive pulmonary disease
(COPD) may partly explain the “obesity paradox” of increased mortality
rate among underweight patients with peripheral arterial disease (PAD).
Summary: There is a paradox in patients with PAD with respect to
weight. In the population with PAD, overweight or obese patients have
a better survival rate than those patients of normal weight, with the
highest mortality seen in the so-called underweight patient (Am J Cardiol
2007;99:1485-90). COPD is emerging as an independent risk factor for
cardiovascular death (Eur Respir J 2006;28:1245-57). Given that COPD
is a potential independent risk factor for cardiovascular death, the authors
sought to investigate whether the presence of COPD may partly explain
the so-called obesity paradox of increased mortality in underweight
patients with PAD.
The study included 2392 patients who underwent major vascular
surgery at a single teaching institution in The Netherlands from January
1990 to November 2006. Patients were classified according to COPD status
and body mass index (BMI) as underweight, normal, overweight, and obese.
Cox regression analysis was used to determine relationships between vari-
ables and all-cause mortality. Median follow-up was 4.37 years (interquartile
range, 1.98-8.47 years).
Overall mortality rates among the underweight, normal, overweight,
and obese patients were 54%, 50%, 40%, and 31%, respectively (P  .001).
Distribution of COPD severity class showed increased prevalence of mod-
erate to severe COPD in underweight patients. BMI as a continuous variable
was associated with increased mortality in the entire population (hazard ratio
[HR], 0.96; 95% confidence interval [CI], 0.94-0.98). Patients classified as
being underweight were also at increased risk for high mortality (HR, 1.42;
95% CI, 1.0-2.01). After adjusting for COPD severity, however, the rela-
tionship between underweight and cardiovascular mortality was no longer
significant (HR, 1.29; 95% CI, 0.91-1.93).
Comment: Why there should be an inverse relationship between BMI
and death is uncertain. Underweight patients may have higher metabolic
rates, lower antioxidant capacity in skeletal muscles, and perhaps increased
systemic inflammatory responses that may contribute to the combination of
lower BMI and morbidity. It is important to note spirometry, which was
used routinely in this study to classify COPD, is not routinely obtained in
vascular disease patients. That 50% of the patients in this study had COPD
when examined with spirometry and only 10% to 15% of patients were
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Thromboembolic Consequences of Subtherapeutic Anticoagulation in
Patients Stabilized on Warfarin Therapy: The Low INR Study
Clark NP, Witt DM, Delate T, and the Endeavors (WARPED) Consortium.
Pharmacology 2008;28:960-7.
Conclusion: Patients with usually stable international normalized ra-
tios (INRs) receiving warfarin who experience a significant subtherapeutic
INR value have a low risk of thromboembolism in the ensuing 90 days.
Summary: Optimal use of warfarin is hampered by unpredictable
pharmacokinetics. In specialized anticoagulation clinics, about 40% of INRs
fall outside the target therapeutic range, and most of these abnormal INR
values are below the target range (Chest 2005;127:1515-22). The authors
conducted a retrospective longitudinal investigation to quantify risk associ-
ated with isolated subtherapeutic anticoagulation. The study was conducted
at Kaiser Permanente Colorado. Anticoagulation services were provided by
a specialized clinical pharmacy anticoagulation service.
A total of 2597 adult patients received warfarin from January 1998 to
December 2005. Of these, 1080 who were classified in the low INR cohort
were matched with 1517 patients with therapeutic INRs. Stable therapeutic
anticoagulation status was defined as two INR values measured at least 2weeks apart within or above the therapeutic range. The low INR cohort was
described as patients with an INR value of 0.5 units below therapeutic
range. The primary outcome variable was anticoagulation-related thrombo-
embolism during the 90 days after the index INR. Secondary outcomes were
times to first occurrence of anticoagulation-related complications (bleeding,
death, or thromboembolism) in the 90 days after the index INR.
Four thromboembolic events (0.4%) occurred in the low INR cohort
and one event (0.1%) in the therapeutic INR cohort (P .214). There were
no differences in proportions of thromboembolism, bleeding, or death
between the two groups.
Comment: This study has several strengths, including its large sample
size, carefully defined patient population, and essentially complete follow-up
in outcome assessment of the patients in this anticoagulation clinic. Al-
though not many events were documented, approximately 40% of the
patients managed in this anticoagulation clinic were in the low INR cohort.
Therefore the data therefore seem fairly strong and indicate a single low INR
value is of very little consequence in a patient with an otherwise stable
anticoagulation profile. The findings do not support bridge therapy with
heparins in patients previously stable on warfarin who have a period of
subtherapeutic anticoagulation. Of course, this was a retrospective study;
therefore, capture of outcome events may have been incomplete. Neverthe-
less, it does not appear one should not become too concerned when a
patient, who is otherwise stable on warfarin anticoagulation, presents with a
diminished INR.
